Anti-Malarial Compounds Targeting Non-Erythrocytic Plasmodium Stages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malaria lack effective drugs that can target non-erythrocytic stages of the Plasmodium parasite, leading to ongoing transmission and severe health issues, especially in developing countries, with growing resistance to existing anti-malarial drugs.
Innovation Solution
Development of compounds identified through quantitative high-throughput screening (qHTS) that inhibit Plasmodium parasite growth, particularly in non-erythrocytic stages, including gametocytes, which can be administered alone or in combination with artemisinin and other anti-malarial compounds to treat and prevent malaria transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-malarial drugs are used, then erythrocytic stage parasites are treated, but non-erythrocytic stages (liver and gametocytes) remain untreated leading to ongoing transmission
Solution Approach 1:
The patent identifies compounds that can target multiple stages of the Plasmodium lifecycle simultaneously - liver stages, gametocytes, and erythrocytic stages - making a single compound capable of performing multiple therapeutic functions that previously required separate treatments
Solution Approach 2:
The patent segments the malaria treatment approach by identifying compounds with specific stage-selective activity, allowing targeted intervention at non-erythrocytic stages (liver and gametocytes) separate from erythrocytic stage treatment
2Reliability
If existing anti-malarial drugs are used, then some parasite stages are controlled, but drug resistance develops reducing treatment efficacy
Solution Approach 1:
The patent employs compounds with novel chemical structures and mechanisms of action that differ from existing anti-malarials, changing the therapeutic parameter space to overcome resistance developed to traditional drugs like chloroquine, artemisinin, and mefloquine
3Measurement precision
If comprehensive high-throughput screening is performed, then compounds targeting non-erythrocytic stages are identified, but screening complexity and resource requirements increase
Solution Approach 1:
The patent uses cell-based assays with Plasmodium-infected cells as intermediaries to screen compound libraries, allowing identification of anti-malarial compounds through measurable effects on parasite growth and development while managing screening complexity through standardized biological readouts
Data Source
AI summary
The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of Plasmodium organisms, and especially Plasmodium falciparum, thereby preventing or blocking transmission of malaria as well as treating malaria infection.